Polaryx Therapeutics (PLYX) Q3 2026 earnings summary

Executive summary

• Clinical-stage rare-disease pipeline led by PLX-200; no approved products or product-sale revenue, with SOTERIA Phase 2 basket trial initiation targeted for Q4 2026.

• Q3 net loss was $3.3M; cash was $8.4M at September 30, 2026, with current operating-plan runway estimated through Q1 2027.

Financial highlights

• Q3 2026 operating expenses rose to $3.3M from $974K, driven by R&D of $2.5M versus $514K; net loss was $3.3M versus $1.4M, including $456K of 2025 direct-listing costs.

• 9M 2026 operating expenses were $6.7M versus $6.9M; net loss narrowed to $7.3M from $7.5M, partly reflecting the absence of $4.3M of 2025 non-recurring gene-therapy license share compensation.

• 9M revenue from product sales remained zero; basic and diluted loss per share was $0.07 in Q3 and $0.15 for 9M 2026, versus $0.03 and $0.17 in 2025.

Outlook and guidance

• SOTERIA trial initiation is expected in Q4 2026; existing cash was estimated to fund operating expenses and capital needs through Q1 2027, subject to assumptions that may prove inaccurate.

• R&D and G&A expenses are expected to increase substantially as clinical programs advance, preclinical programs progress, and public-company and potential commercialization infrastructure expands.

• Additional capital will be needed beyond Q1 2027; financing may include equity, debt, collaborations, or licensing, with no assurance of acceptable terms or availability.